Physician
Endocrinology
Dr. Carla J. Greenbaum, MD
|
|
Give Review
Carla Greenbaum is an expert in the field of Endocrinology. Carla Greenbaum has written publications. He has 100 publications published with PubMed. The lastest publication is: 'Selective extraction of an intrinsic fat-cell plasma-membrane glycoprotein by Triton X-100. Correlation with [3H]cytochalasin B binding activity.'
Publications
- The Development and Utility of a Novel Scale That Quantifies the Glycemic Progression Toward Type 1 Diabetes Over 6 Months.
- Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?
- Heterogeneity in recent onset type 1 diabetes - a clinical trial perspective.
- The Effect of DPT-1 Intravenous Insulin Infusion and Daily Subcutaneous Insulin on Endogenous Insulin Secretion and Postprandial Glucose Tolerance.
- A New Approach for Diagnosing Type 1 Diabetes in Autoantibody-Positive Individuals Based on Prediction and Natural History.
- Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes.
- Recognition of post-translationally modified glutamic acid decarboxylase 65 epitopes in subjects with type 1 diabetes.
- Residual C-peptide in type 1 diabetes: what do we really know?
- Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.
- Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: Follow-Up One Year After Cessation of Treatment.
- B-Lymphocyte Depletion with Rituximab and Beta-Cell Function: Two-Year Results.
- Use of a "fuzzy logic" controller in a closed-loop artificial pancreas.
- Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologi...
- The Acceleration of the Loss of the First-Phase Insulin Response during the Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants.
- Response to Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes...
- Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
- CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring.
- IL-2 therapy in type 1 diabetes: "Trials" and tribulations.
- Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function.
- Fall in C-peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite TrialNet Data.
- Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes.
- Perspective: Rethink the immune connection.
- Making progress: preserving beta cells in type 1 diabetes.
- Comment on: Atkinson. It's Time to Consider Changing the Rules: The Rationale for Rethinking Control Groups in Clinical Trials Aimed at Reversing Type 1 Diabetes. Diab...
- Interaction of onset and duration of diabetes on the percent of gad and ia-2 antibody-positive subjects in the type 1 diabetes genetics consortium database.
- Omental roll-up: a technique for islet engraftment in a large animal model.
- Changes in autoreactive T cell avidity during type 1 diabetes development.
- Type 1 diabetes mellitus: primary, secondary, and tertiary prevention.
- Standardization of C-peptide measurements.
- Use of oral glucose minimal model-derived index of insulin sensitivity in subjects with early type 1 diabetes mellitus.
- Editorial: The role of glucagon in postprandial hyperglycemia--the jury's still out.
- International comparison of C-peptide measurements.
- Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives.
- Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study.
- Progress, but not yet ready for clinical use: interrupting immune-mediated destruction of pancreatic beta cells in type 1 diabetes.
- Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1.
- Non-invasive imaging of beta cell mass: a quantitative analysis.
- Autoimmunity to islet proteins in children diagnosed with new-onset diabetes.
- Systematic screening of potential beta-cell imaging agents.
- C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001.
- Type 1 diabetes intervention trials: what have we learned? A critical review of selected intervention trials.
- Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
- Dynamic perifusion to maintain and assess isolated pancreatic islets.
- Assessment of CD4+ T Cell Responses to Glutamic Acid Decarboxylase 65 Using DQ8 Tetramers Reveals a Pathogenic Role of GAD65 121-140 and GAD65 250-266 in T1D Development.
- Avidity-Dependent Programming of Autoreactive T Cells in T1D.
- Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease.
- Multiple Autoimmune-Associated Variants Confer Decreased IL-2R Signaling in CD4(+)CD25(hi) T Cells of Type 1 Diabetic and Multiple Sclerosis Patients.
- Neurodevelopmental outcome at early school age of children born to mothers with gestational diabetes.
- School-age children born to diabetic mothers and to mothers with gestational diabetes exhibit a high rate of inattention and fine and gross motor impairment.
- Comparison of the motor development of school-age children born to mothers with and without diabetes mellitus.
- The antibody response to bacteriophage is linked to the lymphopenia gene in congenic BioBreeding rats.
- Effect of rituximab on human in vivo antibody immune responses.
- Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects.
- Accumulation of(125)iodine labeled interleukin-2 in the pancreas of NOD mice.
- Persistence is the twin sister of excellence: an important lesson for attempts to prevent and reverse type 1 diabetes.
- Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes.
- Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes.
- Altered B Cell Homeostasis Is Associated with Type I Diabetes and Carriers of the PTPN22 Allelic Variant.
- CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope.
- The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells.
- Future intervention trials in type 1 diabetes.
- Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type I diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team.
- Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects.
- The Fourth International Workshop on the Standardisation of Insulin Autoantibody Workshop.
- Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
- Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes.
- Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins.
- Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
- Role of insulin resistance in predicting progression to type 1 diabetes.
- Functional islet-specific Treg can be generated from CD4+CD25- T cells of healthy and type 1 diabetic subjects.
- Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
- The effect of age on insulin sensitivity and insulin secretion in first-degree relatives of type 1 diabetic patients: a population analysis.
- Male sex increases the risk of autoimmunity but not type 1 diabetes.
- Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects.
- Short-term IL-1beta blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes.
- Major histocompatibility complex class I molecule expression is normal on peripheral blood lymphocytes from patients with insulin-dependent diabetes mellitus.
- Conformation-dependent GAD65 autoantibodies in diabetes.
- The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes.
- GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes.
- Latent autoimmune diabetes in adults (LADA) should be less latent.
- High frequency of abnormal glucose tolerance in DQA1*0102/DQB1*0602 relatives identified as part of the Diabetes Prevention Trial--Type 1 Diabetes.
- Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.
- Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria.
- Low serum conditions for in vitro generation of human macrophages with macrophage colony stimulating factor.
- Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1.
- Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM.
- Short-term responses to periodontal therapy in insulin-dependent diabetic patients.
- Prospective evaluation of beta-cell function in insulin autoantibody-positive relatives of insulin-dependent diabetic patients.
- Nonprogression of subclinical beta-cell dysfunction among first-degree relatives of IDDM patients. 5-yr follow-up of the Seattle Family Study.
- Insulin antibodies and insulin autoantibodies.
- Intra-islet insulin permits glucose to directly suppress pancreatic A cell function.
- Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorb...
- Fifth International Serum Exchange Workshop for Insulin Autoantibody (IAA) Standardization. The Immunology and Diabetes Workshops and participating laboratories.
- Improved specificity of ICA assays in the Fourth International Immunology of Diabetes Serum Exchange Workshop.
- Increased specificity and sensitivity of insulin antibody measurements in autoimmune thyroid disease and type I diabetes.
- Selective extraction of an intrinsic fat-cell plasma-membrane glycoprotein by Triton X-100. Correlation with [3H]cytochalasin B binding activity.
- Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation.
- Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with typ...
- Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients.
Schools
Brown University Alpert Medical School
Swedish Med Center
University Wa Med Center
Doctors Specialties
- Family Medicine
- Endocrinology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- First Health (Coventry Health Care) PPO
- Connect
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Heritage Plus
- Heritage Signature
- Preferred Provider Network PPN
- Tricare
- Choice Plus POS
- Options PPO
- United Healthcare
Education
-
Swedish Medical Center
Hospital
-
University of Washington Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Scott S. Itano, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David M. Siebert, MD |
|
|
Dr. David D. Nguyen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine L. Harris, MD |
|
|
Dr. William E. Neighbor Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Billie J. Fellner, MD |
|
|
Dr. Richard A. Pellerin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony J. Desantis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shauna S. Runchey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gunjan L. Tykodi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gal Omry Orbach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Claire Waltman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew D. Davies, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dace L. Trence, MD
This Doctor is OpenDoctor Recommended.
|